PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of
a new generation of targeted treatments for cancer and immunologic diseases.
The company receives royalties for products licensed under its patents.
Company Presentations & Events
News Releases
07/29/10
PDL BioPharma to Present at BMO Capital Markets' 10th Annual Focus on Healthcare Conference
07/28/10
PDL BioPharma Announces Second Quarter 2010 Financial Results
